Hilltop National Bank Purchases Shares of 8,856 Edwards Lifesciences Corporation $EW

Key Points

• Hilltop National Bank acquired 8,856 shares of Edwards Lifesciences Corporation in the second quarter, valued at approximately $693,000.
• Multiple hedge funds have increased their positions in Edwards Lifesciences, with Jennison Associates LLC leading by boosting holdings by 34.3% in the first quarter.
• Analysts have raised price targets for Edwards Lifesciences, with a consensus target of $86.61, reflecting a mix of ratings from "Strong Buy" to "Sell."

Hilltop National Bank bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 8,856 shares of the medical research company's stock, valued at approximately $693,000.

Other hedge funds also recently modified their holdings of the company. Jennison Associates LLC boosted its holdings in Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after acquiring an additional 2,576,383 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Edwards Lifesciences by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company's stock worth $491,673,000 after purchasing an additional 264,311 shares during the last quarter. Nuveen LLC purchased a new position in Edwards Lifesciences during the first quarter worth about $330,881,000. Invesco Ltd. boosted its holdings in Edwards Lifesciences by 2.6% during the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company's stock worth $310,773,000 after purchasing an additional 107,241 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Edwards Lifesciences by 5.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company's stock worth $287,140,000 after buying an additional 198,882 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Evercore ISI boosted their target price on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a research note on Friday, July 25th. Deutsche Bank Aktiengesellschaft boosted their price objective on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Wells Fargo & Company boosted their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a report on Thursday, August 7th. Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Finally, William Blair raised shares of Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of "Moderate Buy" and a consensus price target of $86.61.

Edwards Lifesciences Price Performance

NYSE EW opened at $77.03 on Friday. The company has a market cap of $45.22 billion, a PE ratio of 11.08, a price-to-earnings-growth ratio of 3.69 and a beta of 1.05. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm's 50-day simple moving average is $78.50 and its two-hundred day simple moving average is $75.94.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.